Effects of inducible nitric oxide synthase inhibition on the rat tail vascular bed reactivity three days after myocardium infarction

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 4, 2005, Pages 321-326

  Sartório, Carmem Luíza ^a   Dias Pinto, Valber ^a   De Salles Cutini, Gustavo Julio ^a   Vassallo, Dalton Valentim ^a   Stefanon, Ivanita ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Inducible nitric oxide synthase; Myocardial infarction; Rat tail vascular bed; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRATE; NITRITE; PHENYLEPHRINE; S METHYLPSEUDOTHIOUREA; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INHIBITION; GENE; GENE EXPRESSION; HEART INFARCTION; HEMODYNAMICS; INFLAMMATION; INOS GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TAIL ARTERY; VASOCONSTRICTION; VASODILATATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MALE; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; TAIL; VASODILATION;

EID: 15744368378     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000156822.58081.be     Document Type: Article

References (39)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
2. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isoenzymes: Characterization, purification, molecular cloning, and functions. Hypertension. 1994;23:1121-1131.
3. Hecker M, Cattaruzza M, Wagner AH. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol. 1999;32:9-16.
4. Papapetropoulos A, Rudic RD, Sessa W. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res. 1999;43:509-520.
5. Stoclet JC, Muller B, György K, et al. The inducible nitric oxide synthase in vascular and cardiac tissue. Eur J Pharmacol. 1999;375:139-155.
6. Saito T, Hu F, Tayara L, et al. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol. 2002;283:H339-H345.
7. Szabó C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiorea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA. 1994;91:12472-12476.
8. de Beider AJ, Radomski MW, Why HJF, et al. Nitric oxide and the pathogenesis of heart muscle disease. Eur J Clin Invest. 1995;25:1-8.
9. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087-1094.
10. Wildhirt SM, Suzuki H, Wolf WF, et al. S-methylisothiourea inhibits inducible nitric oxide synthase and improves left ventricular performance after acute myocardial infarction. Biochem Biophys Res Commun. 1996;227:328-333.
11. Wildhirt SM, Suzuki H, Horstman D, et al. Selective modulation of inducible nitric oxide synthase isoenzyme in myocardial infarction. Circulation. 1997;96:1616-1623.
12. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 1998;30:1215-1223.
13. Katz SD, Ramanath R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilatation in de forearm circulation. Circulation. 1994;90:12-16.
14. Xia Y, Roman LJ, Masters BSS, et al. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem. 1998;273:22635-22639.
15. Bauersachs J, Bouloumié A, Fraccarollo D, et al. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 1999;100:292-298.
16. Bauersachs J, Fleming I, Fracarollo D, et al. Prevention of endothelial dysfunction in heart failure by vitamin E: attenuation of vascular superoxide anion formation and increase in soluble guanylyl cyclase expression. Cardiovasc Res. 2001;51:344-350.
17. Miller AA, Megson IL, Gray GA. Inducible nitric oxide synthase-derived superoxide contributes to hyperactivity in small mesenteric arteries from a rat model of chronic heart failure. Br J Pharmacol. 2000;131:29-36.
18. Garvey EP, Oplinger JA, Tanoury GJ, et al. Potent and selective inhibition of human nitric oxide synthases. J Biol Chem. 1994;269:26669-26676.
19. Mill JG, Stefanon I, Leite CM, et al. Changes in performance of the surviving myocardium after left ventricular infarction in rats. Cardiovasc Res. 1990;24:748-753.
20. Stathopulos PB, Lu X, Shen J, et al. Increased L-arginine uptake and inducible nitric oxide synthase activity in aortas of rats with heart failure. Am J Physiol. 2001;280:H859-H867.
21. Heba G, Krzeminski T, Porc M, et al. Time course of tumor necrosis factor-α, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats. J Vasc Res. 2001;38:288-299.
22. 3, in plasma after experimental myocardial infarction. J Mol Cell Cardiol. 1997;29:1-9.
23. Vivaldi MT, Kloner RA, Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol. 1985;121:522-530.
24. Misko TP, Schilling RJ, Salvemini D, et al. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993;214:11-16.
25. Grove DS. Quantitative real-time polymerase chain reaction for the core facility using TaqMan and the Perkin-Elmer/Applied Biosystems Division 7700 sequence detector. J Biomol Tech. 1999;10:11-16.
26. Baggia S, Perkins K, Greenberg B. Endothelium-dependent relaxation is not uniformly impaired in chronic heart failure. J Cardiovasc Pharmacol. 1997;29:389-396.
27. Teerlink JR, Gray GA, Clozel M, et al. Increased vascular responsiveness to norepinephrine in rats with heart failure is endothelium dependent: dissociation of basal and stimulated nitric oxide release. Circulation. 1994;89:393-401.
28. Da Cunha, Stefanen I, Mill JG. Role of nitric oxide in mediating cardiovascular alterations accompanying heart failure in rats. Can J Physiol Pharmacol. 2004;82:372-379.
29. Teerlink JR, Clozel M, Fischli W, et al. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. J Am Coll Cardiol. 1993;22:615-620.
30. Bauersachs J, Fracarollo D, Galuppo P, et al. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure. Cardiovasc Res. 2000;47:142-149.
31. Didion SP, Carmines PK, Ikenaga H, et al. Enhanced constrictor responses of skeletal muscle arterioles during chronic myocardial infarction. Am J Physiol. 1997;273:H1502-H1508.
32. Stewart DJ, Kubac G, Costello KB, et al. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
33. Paulus WJ. Endothelial control of vascular and myocardial function in heart failure. Cardiovasc Drugs Ther. 1994;8:3, 437-446.
34. Vanhoutte PM. Endothelium-dependent responses in congestive heart failure. J Mol Cell Cardiol. 1996;28:2223-2240.
35. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60.
36. Feng Q, Fortin AJ, Lu X, et al. Effects of L-arginine on endothelial and cardiac function in rats with heart failure. Eur J Pharmacol. 1999;376:37-44.
37. Kimura A, Roseto J, Suh KY, et al. Dexamethasone on inducible nitric oxide synthase and nitrite/nitrate production in myocardial infarction. Proc Soc Exp Biol Med. 1998;219:138-143.
38. Bouloumié A, Bauersachs J, Linz W, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and Superoxide anion production. Hypertension. 1997;30:934-941.
39. Rossoni LV, Salaices M, Miguel M, et al. Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol. 2002;283:H2110-H2118.